Contineum Therapeutics, Inc. Class A Common Stock Price & Performance (CTNM)

Contineum Therapeutics is gearing up for a transformative 2025, with plans to conduct up to six clinical trials. Key data readouts include PIPE-791's Phase 1b PET trial in Q2 and PIPE-307's Phase 2 trial for multiple sclerosis in H2. The company’s $204.8M cash position ensures runway through 2027.12

JonesTrading has initiated coverage on Contineum Therapeutics with a “Buy” rating and a $23 price target. The recommendation highlights the potential of the company’s lead assets, PIPE-791 and PIPE-307, targeting high unmet needs in neuroscience and immunology. PIPE-791 trials address pulmonary fibrosis and progressive MS.3

Despite a Q4 2024 net loss of $14.6M, Contineum’s robust $204.8M cash reserve offers a financial cushion through 2027. Increased R&D spending reflects progress in clinical trials, including PIPE-791 and PIPE-307. Investors focus on near-term catalysts, such as data from multiple sclerosis and PET imaging trials in 2025.12